- Previous: New Treatment Recommended for Asian Chronic Hepatitis C Patients
- Main
- Next: Breaking the Hepatitis C Social Stigma
Alinia Tablets and Hepatitis C
August 24, 2007
For HCV genotype 1 patients who have failed to respond to standard therapy (peginterferon and ribavirin), Romark Laboratories has designed a clinical trial to test the safety and effectiveness of Alinia (nitazoxanide). Learn more about the Phase II clinical trial during which nitazoxanide tablets are administered in combination with Pegasys and Copegus, in 60 patients with the most common genotype in North America.
RxTrials Institute Drug Pipeline Alert
Aug. 20, 2007 | Vol. 5 No. 163
http://fdanews.com
Romark Begins Trial of Alinia for Chronic Hepatitis C
Romark Laboratories has initiated a Phase II clinical trial of Alinia for treating chronic hepatitis C in the U.S.
According to Romark, the clinical trial is designed to evaluate the effectiveness and safety of Alinia (nitazoxanide) tablets administered in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in 60 patients with chronic hepatitis C genotype 1 who have failed to respond to standard therapy (peginterferon and ribavirin).
The trial is part of the company’s Studies to Evaluate Alinia for Treatment of Hepatitis C (STEALTH C) clinical development program, a series of clinical trials designed to evaluate the safety and efficacy of Alinia tablets in combination with peginterferon or peginterferon and ribavirin in patients with chronic hepatitis C.
The trial is designed to evaluate the effectiveness and safety of Alinia administered 500 mg twice daily for four weeks followed by Alinia-Pegasys-Copegus combination therapy for 48 weeks compared to placebo for four weeks followed by placebo-Pegasys-Copegus combination therapy for 48 weeks, which is the standard of care.
Posted by Editors at August 24, 2007 4:21 PM
Requirements for using and reposting articles
Site Topics
Frequently Asked Questions
Some of our most commonly asked questions and our answers to them.
HCV Symptoms
You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.
Lab Tests
What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.
Hepatitis C Genotypes
Learn about Hepatitis C Genotypes and their variants.
Viral Load
Provides detailed information on how to analyze and interpret viral load numbers as well as a link to a convenient Viral Load Chart.
What is...?
Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.
HCV Medicines
Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.
Glossary
Commonly used medical terms and definitions.
Hepatitis C Doctors
A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.
Biopsy Info
A comprehensive resource of information relating to the liver biopsy.
Cirrhosis
Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.
Liver Cancer
Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.
Liver Disease Medicines
An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.
Hep-Central Email List
Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.
HCV Links
Convenient links to other sites external to Hepatitis-Central.
-
HCV Transmission
Information about the transmission of Hepatitis C.
HCV Natural Remedies
A number of herbal products useful in the management of liver disease.
HCV Books
Recommended reading for those interested in hepatitis information.
Hepatitis C Forum
A Bulletin Board for discussions on hepatitis, treatments, etc.
Hepatitis C Activism
An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.
Advertisement
